[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know",
    "summary": "Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=f30e0c01903d56c3c794f6746a2ee3364d58eed44381687ccca8ae54eb8c8dd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744321813,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know",
      "id": 133880853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=f30e0c01903d56c3c794f6746a2ee3364d58eed44381687ccca8ae54eb8c8dd3"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=3befafec329d451e373fcce21fe071d475ec2cf1d221e7c7804c2191057c5ac9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744303020,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 133888433,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=3befafec329d451e373fcce21fe071d475ec2cf1d221e7c7804c2191057c5ac9"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise",
    "summary": "GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of the main indices. The Value Fund finished the first quarter +3.0% net of fees and expenses net […]",
    "url": "https://finnhub.io/api/news?id=c268b196989275dbe168e2cc0a3006c64deb70fa342b7e45980edeea7a85accd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744289750,
      "headline": "Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise",
      "id": 133844451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of the main indices. The Value Fund finished the first quarter +3.0% net of fees and expenses net […]",
      "url": "https://finnhub.io/api/news?id=c268b196989275dbe168e2cc0a3006c64deb70fa342b7e45980edeea7a85accd"
    }
  },
  {
    "ts": null,
    "headline": "GreensKeeper Q1 2025 Portfolio Update",
    "summary": "GreensKeeper Q1 2025 Portfolio Update",
    "url": "https://finnhub.io/api/news?id=4664c145a0432496620b2c3ff78498b0450dbb30def151e4b547e1d0becc76b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744275300,
      "headline": "GreensKeeper Q1 2025 Portfolio Update",
      "id": 133843201,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4664c145a0432496620b2c3ff78498b0450dbb30def151e4b547e1d0becc76b7"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Growth Strategy Q1 2025 Commentary",
    "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the first quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=da2e1e3d9495f6befc4628d9a57d186fa9b60f0850b60f20f64dc6cc8809362a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744273140,
      "headline": "ClearBridge Growth Strategy Q1 2025 Commentary",
      "id": 133843128,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the first quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=da2e1e3d9495f6befc4628d9a57d186fa9b60f0850b60f20f64dc6cc8809362a"
    }
  },
  {
    "ts": null,
    "headline": "We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.",
    "summary": "Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs.  Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims that Buffett applauded President Trump's economic policies.  In an interview with CBS News in March, Buffett called tariffs an \"act of war.\"",
    "url": "https://finnhub.io/api/news?id=138b8e7300fc164da53a20cc358507d8320bc673abe7ecc9062462b7cec975c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744271520,
      "headline": "We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.",
      "id": 133843834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs.  Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims that Buffett applauded President Trump's economic policies.  In an interview with CBS News in March, Buffett called tariffs an \"act of war.\"",
      "url": "https://finnhub.io/api/news?id=138b8e7300fc164da53a20cc358507d8320bc673abe7ecc9062462b7cec975c3"
    }
  }
]